IMMUNOGEN COMPLEXES OF HUMAN MONOCLONAL ANTIBODIES AND HIV-1 GP120

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 预防疫苗是控制HIV/AIDS流行的迫切需要，潜在的疫苗平台可以包括HIV-1包膜gp120抗原/抗体复合体，该复合体与选定的抗gp120单抗(MAb)结合后，增强了感兴趣的中和表位的抗原性和免疫原性。在形成这些络合物时，可以分离出化学计量未知的多个不同大小的物种(通过尺寸排除层析确定)。SAXS可能为了解免疫原复合体的形成提供必要的信息，从而指导疫苗的发现。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. A prophylactic vaccine is much needed for controlling the HIV/AIDS pandemics, and a potential vaccine platform can comprise of an HIV-1 envelope gp120 antigen/antibody complex made with a selected anti-gp120 monoclonal antibody (mAb) that upon binding to the antigen augments the antigenicity and immunogenicity of a neutralizing epitope of interest. When forming these complexes, multiple species of different sizes (determined by size exclusion chromatography) with unknown stoichiometry can be isolated. SAXS may provide necessary information in understanding the immunogen complex formation, hence guiding the vaccine discovery.